(firstQuint)A Phase I Study of ABT 510 for Newly Diagnosed Glioblastoma Multiforme.

 1.

 To describe the toxicity associated with this regimen in adult patients with newly diagnosed glioblastoma multiforme.

 2.

 To determine the duration of disease free survival and overall survival associated with this therapy.

 3.

 Evaluate thrombospondin 1 (TSP-1) and 2 (TSP-2) in tumor vs.

 corresponding normal tissue using quantitative real time Polymerase Chain Reaction (Q-RT-PCR).

 4.

 Determine the effect of ABT 510 on tumor permeability and tumor blood volume as measured by non-invasive Magnetic Resonance Imaging (MRI).

.

 A Phase I Study of ABT 510 for Newly Diagnosed Glioblastoma Multiforme@highlight

To determine the maximum tolerated dose of ABT 510 when administered concurrent with radiation therapy for patients with newly diagnosed glioblastoma multiforme.

